HK1246694A1 - α胸腺肽用於脓毒症治疗的用途 - Google Patents

α胸腺肽用於脓毒症治疗的用途 Download PDF

Info

Publication number
HK1246694A1
HK1246694A1 HK18106506.4A HK18106506A HK1246694A1 HK 1246694 A1 HK1246694 A1 HK 1246694A1 HK 18106506 A HK18106506 A HK 18106506A HK 1246694 A1 HK1246694 A1 HK 1246694A1
Authority
HK
Hong Kong
Prior art keywords
sepsis
days
thymosin peptide
alpha
administered
Prior art date
Application number
HK18106506.4A
Other languages
English (en)
Chinese (zh)
Inventor
管向東
管向东
吳健鋒
吴健锋
C．塔特希爾
C.塔特希尔
Original Assignee
Sciclone Pharmaceuticals International (Sg) Pte. Ltd.
中山大学附属第一医院
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciclone Pharmaceuticals International (Sg) Pte. Ltd., 中山大学附属第一医院 filed Critical Sciclone Pharmaceuticals International (Sg) Pte. Ltd.
Publication of HK1246694A1 publication Critical patent/HK1246694A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK18106506.4A 2012-03-30 2018-05-18 α胸腺肽用於脓毒症治疗的用途 HK1246694A1 (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261618563P 2012-03-30 2012-03-30
US61/618,563 2012-03-30
US201261643824P 2012-05-07 2012-05-07
US61/643,824 2012-05-07
US13/835,107 US20130296223A1 (en) 2012-03-30 2013-03-15 Use of thymosin alpha for the treatment of sepsis
US13/835,107 2013-03-15

Publications (1)

Publication Number Publication Date
HK1246694A1 true HK1246694A1 (zh) 2018-09-14

Family

ID=49261395

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18106506.4A HK1246694A1 (zh) 2012-03-30 2018-05-18 α胸腺肽用於脓毒症治疗的用途

Country Status (8)

Country Link
US (5) US20130296223A1 (cg-RX-API-DMAC7.html)
EP (2) EP3741386A1 (cg-RX-API-DMAC7.html)
JP (6) JP2015514093A (cg-RX-API-DMAC7.html)
KR (1) KR20150048663A (cg-RX-API-DMAC7.html)
CN (2) CN107519483A (cg-RX-API-DMAC7.html)
CA (1) CA2866435A1 (cg-RX-API-DMAC7.html)
HK (1) HK1246694A1 (cg-RX-API-DMAC7.html)
WO (1) WO2013149030A2 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2956429A1 (en) * 2014-08-12 2016-02-18 Arsanis Biosciences Gmbh Predicting s. aureus disease
WO2019028448A1 (en) * 2017-08-04 2019-02-07 The Johns Hopkins University APPLICATION FOR EARLY PREDICTION OF SEPTIC SHOCK WAITING
US11504071B2 (en) * 2018-04-10 2022-11-22 Hill-Rom Services, Inc. Patient risk assessment based on data from multiple sources in a healthcare facility
LT3781210T (lt) * 2018-04-20 2024-09-10 Combioxin Sa Gydymas hipotenzijos su sepsiu arba septiniu šoku
EP4370129A1 (en) 2021-07-12 2024-05-22 2N Pharma ApS Carnitine-palmitoyl-transferase-1 (cpt-1) inhibitors for use in a method of preventing or treating sepsis in a mammalian subject

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4079127A (en) 1976-10-28 1978-03-14 Board Of Regents Of The University Of Texas Thymosin alpha 1
TW252045B (cg-RX-API-DMAC7.html) * 1993-10-07 1995-07-21 Allan L Goldstein
WO1995009647A1 (en) * 1993-10-07 1995-04-13 The George Washington University Medical Center METHOD OF TREATING SEPTIC SHOCK USING THYMOSIN-α¿1?
US5972933A (en) * 1998-01-08 1999-10-26 Ed. Geistlich Sohne Ag Fur Chemische Industrie Method of treating microbial infections
UA80957C2 (en) 2001-11-01 2007-11-26 Sciclone Pharmaceuticals Inc Method of administering a thymosin alpha 1 peptide
KR20050086819A (ko) * 2002-11-25 2005-08-30 시클론 파마수티컬 인코포레이티드 알파 티모신을 사용한 방사능 손상에 대한 보호방법
CA2622193A1 (en) * 2005-09-29 2007-04-12 Nektar Therapeutics Antibiotic formulations, unit doses, kits, and methods
CN101020048A (zh) * 2007-02-12 2007-08-22 广东天普生化医药股份有限公司 一种用于治疗脓毒症的药物组合物
CA2679626C (en) * 2007-03-21 2012-10-23 Bausch & Lomb Incorporated Fluoroquinolones for treating, reducing, ameliorating, or preventing infections caused by antibacterial-drug resistant bacteria
JP2011506436A (ja) * 2007-12-12 2011-03-03 サイクローン・ファーマシューティカルズ・インコーポレイテッド 細胞傷害性ｔリンパ球抗原４（ｃｔｌａ４）に対する抗体と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法
CN101514228A (zh) * 2008-02-21 2009-08-26 张卓兵 N-端修饰的人胸腺肽α1复合物及其制备方法
JP2012526149A (ja) * 2009-05-08 2012-10-25 サイクローン・ファーマシューティカルズ・インコーポレイテッド ワクチン増強剤としてのαチモシンペプチド
JP2013520475A (ja) * 2010-02-25 2013-06-06 アゲンニックス・アーゲー 重症敗血症の治療における経口ラクトフェリン
CA2826875A1 (en) * 2011-02-09 2012-08-16 Sciclone Pharmaceuticals, Inc. Thymosin alpha peptide for preventing, reducing the severity of, and treating infection

Also Published As

Publication number Publication date
US20210106656A1 (en) 2021-04-15
JP2021100983A (ja) 2021-07-08
WO2013149030A2 (en) 2013-10-03
HK1207314A1 (en) 2016-01-29
CA2866435A1 (en) 2013-10-03
US20130296223A1 (en) 2013-11-07
EP3741386A1 (en) 2020-11-25
JP2015514093A (ja) 2015-05-18
JP2017214377A (ja) 2017-12-07
CN107519483A (zh) 2017-12-29
EP2841088B1 (en) 2020-06-17
KR20150048663A (ko) 2015-05-07
EP2841088A2 (en) 2015-03-04
US20150024994A1 (en) 2015-01-22
JP2025107346A (ja) 2025-07-17
JP2019156854A (ja) 2019-09-19
CN105338996A (zh) 2016-02-17
US20240091314A1 (en) 2024-03-21
US20180236036A1 (en) 2018-08-23
JP2022176345A (ja) 2022-11-25
EP2841088A4 (en) 2015-10-14

Similar Documents

Publication Publication Date Title
US20240091314A1 (en) Use of thymosin alpha for the treatment of sepsis
Egea et al. GM-CSF: a role in immune and inflammatory reactions in the intestine
Schroll et al. Lipocalin‐2 ameliorates granulocyte functionality
Heinen et al. IGF1 treatment improves cardiac remodeling after infarction by targeting myeloid cells
Blake et al. Role of IL-17 and IL-22 in autoimmunity and cancer
US8212007B2 (en) Expression and purification of HIP/PAP and uses therefor
Baranowsky et al. Procalcitonin exerts a mediator role in septic shock through the calcitonin gene-related peptide receptor
JP5746761B2 (ja) 気道感染症の処置のための方法及び医薬組成物
US9227997B2 (en) Composition for treating sepsis or septic shock comprising the peptide originated from the Smad6
AU2021202603A1 (en) Novel therapy
AU2018329850A1 (en) Modified fibroblast growth factor 21 (FGF-21) for use in methods for treating nonalcoholic steatohepatitis (NASH)
WO2021138582A1 (en) Fusion proteins and methods of use thereof
US20230416318A1 (en) Osteoanabolism by 14-3-3zeta
US20200121773A1 (en) Compositions and methods for manufacturing bacteriophage cancer vaccines and uses thereof
HK40035899A (en) Use of thymosin alpha for the treatment of sepsis
EP4138881B1 (en) Composition comprising dnase i for use in a method of preventing the activation of the aim2 inflammasome
HK1207314B (en) Use of thymosin alpha for the treatment of sepsis
US20250171546A1 (en) Dupilumab for treatment of covid-19
US20090214469A1 (en) Methods and Compositions for the Treatment of Sepsis
Patel Investigating the Role of Dectin-1 as a Marker of Profibrotic Macrophages in the Progression of Pulmonary Fibrosis
Dagenais Regulation of tissue homeostasis and tumorigenesis by innate immunity and cell death pathways
WO2013040840A1 (zh) 预防、诊断、治疗、预后全身性细菌感染疾病的方法和试剂
Cavaillon et al. Compartmentalized Activation of Immune Cells During Sepsis and Organ Dysfunction
Javier Munoz et al. Erdheim-Chester Disease: Characteristics and Management